BMS-986278 in Participants With Lung Fibrosis

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis [idiopathic pulmonary fibrosis (IPF) and progressive fibrotic interstitial lung disease (PF-ILD)], to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

  • Study Sponsor: Bristol Myers Squibb

  • Start Date: July 2020

  • Estimated Primary Completion Date: May 2023

  • Phase 2, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and the safety and tolerability of BMS-986278 in participants with pulmonary fibrosis 

Inclusion Criteria:

For the idiopathic pulmonary fibrosis (IPF) Cohort

  • Diagnosis of IPF within 7 years
  • Female and males ≥ 40 years of age

For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort

  • Evidence of progressive ILD within the 24 months before screening
  • Female and male ≥ 21 years of age 

Exclusion Criteria:

  • Women of childbearing potential (WOCBP)
  • Active Smokers
  • Patients with current malignancy
  • History of allergy to BMS-986278 or related compounds

Participating Clinics at Partner ILD Centers